News
-
12 April 2021
Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting -
25 March 2021
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results -
11 March 2021
Immunocore Announces Upcoming Presentations at the American Association for Cancer Research 2021 Annual Meeting -
19 February 2021
Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA -
16 February 2021
Immunocore announces key appointments to management and Board -
9 February 2021
Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement -
5 February 2021
Immunocore Announces Pricing of Upsized Initial Public Offering -
11 January 2021
Immunocore announces closing of $75.0 Million Series C round -
3 December 2020
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 -
23 November 2020
Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma